February 19th 2025
The designation is supported by preliminary data from the ongoing phase 1/2a SECuRE trial.
Conventional imaging may understage prostate cancer, new data suggest
January 3rd 2025“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.
Next steps in research for AI prostate cancer mapping
September 20th 2024"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a multi-institutional, prospective manner," says Shyam Natarjan, PhD.